Arkus Innovation Studios

Erviegas / Hypen — Diagnostic

A Startup Diagnostic commissioned by a portfolio parent to evaluate Hypen, a novel digital insulin injection device venture.

Hypen sits at the intersection of medical devices, digital health, and chronic disease management, with high regulatory and commercialization complexity.

Erviegas commissioned Arkus for an independent, structured read on technology posture, market viability, regulatory pathway, and defensibility to complement internal portfolio judgment.

Market assessment: Addressable market modeling, competitive scan across incumbents and digital-health entrants, and go-to-market feasibility review.

Product and technology review: Technology differentiation, FDA/ANVISA pathway considerations, development stage, and manufacturing posture.

Team and defensibility analysis: Team composition review, IP posture assessment in a crowded category, and defensibility mapping.

Recommendation: Teixeira Framework recommendation delivered via 60-minute debrief to leadership.

The diagnostic delivered an independent evidence layer for portfolio decisioning. Final recommendation bucket and post-assessment capital actions remain pending client-approved disclosure.

Arkus did not advise on retain/divest decisions. Those calls stay with Erviegas, where full portfolio context and capital strategy are held.

Arkus supplied the evaluation structure; final investment decisions remained with portfolio ownership.